title: A Southwest Oncology Group phase II evaluation of fluderabine monophosphate in sarcoma.
authors.affiliation: National Cancer Institute, Bethesda, MD.
authors.forename: M R
authors.initials: MR
authors.lastname: Grever
authors.forename: J
authors.initials: J
authors.lastname: Benedetti
authors.forename: S P
authors.initials: SP
authors.lastname: Balcerzak
authors.forename: S A
authors.initials: SA
authors.lastname: Taylor
authors.forename: T P
authors.initials: TP
authors.lastname: Miller
authors.forename: S R
authors.initials: SR
authors.lastname: Dakhil
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009362:Neoplasm Metastasis; D012509:Sarcoma / Q000188:drug therapy*; D012894:Sleep Stages; D001084:Vidarabine Phosphate / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000964:Antimetabolites, Antineoplastic; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate